Biological agents target directly the pathological process of autoimmune inflammatory rheumatic diseases. Transplacental passage of biological agents differs related to their molecular structure. Human pregnancy experience is limited, the majority of information was derived from isolated case reports, and retrospective studies. Therefore these drugs must be discontinued before or at conception.